News & Views
Project to Develop Ground-Breaking Therapy for CF
Oct 20 2018 Read 630 Times
Researchers from the UK Cystic Fibrosis Gene Therapy Consortium (GTC) including Imperial College London and the Universities of Oxford and Edinburgh, have linked-up with Boehringer Ingelheim and Oxford BioMedica to develop a new viral vector-based gene therapy to take forward to clinical trials.
The partnership builds on pioneering research carried out by the GTC, with contributions from Professor Eric Alton, Professor Uta Griesenbach, Professor Jane Davies and Tracy Harman of Imperial’s National Heart & Lung Institute. It also follows on from early clinical trials of gene therapies for CF in the UK which have shown encouraging results.
Professor Alton, coordinator of the GTC, said: “We have, for the last 17 years, vigorously sought to establish whether gene therapy can become a clinically viable option for patients with CF.
“From the beginning the GTC identified that this goal would require incremental increases in knowledge. We have, therefore, built on our non-viral gene therapy experience to develop a new viral vector-based product which is currently funded by the Health Innovation Challenge Fund (a partnership between the Wellcome Trust and the Department of Health and Social Care) and the Cystic Fibrosis Trust.
“The GTC believes that this partnership provides CF patients with the optimal chance to establish gene therapy as routine clinical practice, relevant to all patients, irrespective of their mutation status and in due course to both prevent lung disease as well as treat established problems.”
Imperial's technology commercialisation company, Imperial Innovations, is acting as the lead on the technology transfer for the partnership.
Andrew Tingey, Director of Healthcare Licensing at Imperial Innovations, said: “The combination of expertise and resources realised by this deal will give the project a unique opportunity to develop an advanced therapy that could significantly impact the lives of thousands of people living with cystic fibrosis and we are delighted to have played the lead role in securing this partnership.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Issue Articles - Review of China market shows real potential for lab companies - Biphenyl Modified Silica Stabilised by Bulky Substituents Laboratory Products - ChIP Kits for H...
View all digital editions
Sep 21 2020 Budapest, Hungary
Sep 22 2020 Moscow, Russia
Sep 29 2020 Utrecht, Holland
Oct 06 2020 Lagos, Nigeria
Oct 06 2020 Digital Forum